ALLO Share Price Performance
US$2.42
1.00 (70.42%)
67.6% undervalued intrinsic discount
US$7.47
Fair Value
Price US$2.42
AnalystConsensusTarget US$7.47
AnalystHighTarget US$13.40
AnalystLowTarget US$1.60
Fair ValueUS$7.47
Share Pricen/a
Allogene Therapeutics, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 30 Fair Values set on narratives written by author
ALLO Community Narratives
AN
Fair Value US$7.47 67.6% undervalued intrinsic discount
Off The Shelf CAR T Therapies Will Reshape Lymphoma And Autoimmune Treatment Trajectories
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$13.4 81.9% undervalued intrinsic discount
MRD Guided Cell Therapy And Autoimmune Focus Will Transform Long Term Opportunity
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$1.6 51.2% overvalued intrinsic discount
Allogeneic CAR T Expectations Will Likely Disappoint As Trial And Cash Runway Risks Mount
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
MRD Guided Cell Therapy And Autoimmune Focus Will Transform Long Term Opportunity
Catalysts About Allogene Therapeutics Allogene Therapeutics develops off the shelf allogeneic CAR T cell therapies for cancer and autoimmune diseases. What are the underlying business or industry changes driving this perspective?Read more
18
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$13.4
81.9% undervalued intrinsic discount
Fair Value
Profit Margin
14.76%
Future PE
69.99x
Price in 2029
US$0
Off The Shelf CAR T Therapies Will Reshape Lymphoma And Autoimmune Treatment Trajectories
Catalysts About Allogene Therapeutics Allogene Therapeutics develops off the shelf allogeneic CAR T cell therapies for cancer and autoimmune diseases. What are the underlying business or industry changes driving this perspective?Read more
77
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$7.47
67.6% undervalued intrinsic discount
Fair Value
Profit Margin
12.51%
Future PE
163.7x
Price in 2029
US$0
Allogeneic CAR T Expectations Will Likely Disappoint As Trial And Cash Runway Risks Mount
Catalysts About Allogene Therapeutics Allogene Therapeutics is a biotechnology company focused on developing off the shelf allogeneic CAR T cell therapies for cancer and autoimmune diseases. What are the underlying business or industry changes driving this perspective?Read more
13
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$1.6
51.2% overvalued intrinsic discount
Fair Value
Profit Margin
10.89%
Future PE
51.85kx
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
MRD Guided Cell Therapy And Autoimmune Focus Will Transform Long Term Opportunity
Fair Value: US$13.4 81.9% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Off The Shelf CAR T Therapies Will Reshape Lymphoma And Autoimmune Treatment Trajectories
Fair Value: US$7.47 67.6% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Allogeneic CAR T Expectations Will Likely Disappoint As Trial And Cash Runway Risks Mount
Fair Value: US$1.6 51.2% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Allogene Therapeutics, Inc. Key Details
About ALLO
- Founded
- 2017
- Employees
- 151
- CEO
- WebsiteView website
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
